SMMT vs. VTRS: Summit Therapeutics vs. Viatris Stock Comparison

November 11, 2026

How do Summit Therapeutics (SMMT) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Summit Therapeutics (SMMT) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SMMT is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Summit Therapeutics (SMMT) and Viatris (VTRS)
Profile Item	SMMT	VTRS
Name	Summit Therapeutics Inc.	Viatris Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	13.06 billion USD	22.83 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	March 5, 2015	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

SMMT

VTRS

GSPC

Summit Therapeutics (SMMT) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Summit Therapeutics (SMMT) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Summit Therapeutics (SMMT) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
Total Return (1Y)	-2.48%	108.98%
Total Return (3Y, Annualized)	116.18%	36.75%
Total Return (5Y, Annualized)	26.89%	11.59%

Risk Profile

Drawdown History

SMMT

VTRS

GSPC

Summit Therapeutics (SMMT) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Summit Therapeutics (SMMT) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Viatris (VTRS) has a non-negative beta of 0.86.

Risk profile metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
Volatility (1Y, Annualized)	75.06%	32.53%
Beta (5Y)	-1.51	0.86
Max Drawdown (5Y)	-87.64%	-45.69%
Avg. Volume (3M)	6.19M	8.87M

Risk-Adjusted Performance

Risk-Return Positioning

SMMT and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
Sharpe Ratio (1Y)	-0.09	3.22
Sortino Ratio (1Y)	-0.13	5.63

Profitability

ROE (TTM)

Both Summit Therapeutics (SMMT) at -220.01% and Viatris (VTRS) at -4.21% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
SMMT: -220.01%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max: 109.18%
Q3: 6.23%
VTRS: -4.21%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
SMMT: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
VTRS: -4.13%
Q1: -4.14%
Min: -17.05%

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Summit Therapeutics (SMMT) at 0.00% and Viatris (VTRS) at 13.85% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
SMMT: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max: 83.12%
Q3: 14.77%
VTRS: 13.85%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
ROE (TTM)	-220.01%	-4.21%
ROA (TTM)	-111.99%	2.91%
Net Margin (TTM)	0.00%	-4.13%
Operating Margin (TTM)	0.00%	13.85%
Gross Margin (TTM)	0.00%	41.13%

Growth

Revenue Growth

Only one side can be read here: Viatris (VTRS) reports revenue growth of -2.98%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Summit Therapeutics (SMMT) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
Revenue Growth (YoY)	--	-2.98%
Revenue Growth (3Y CAGR)	--	-4.20%
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max: 25.13
Q3: 12.13
SMMT: 5.99
Median: 5.52
Q1: 2.47
Min: 0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
VTRS: 1.55
Min: 0.10

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Summit Therapeutics (SMMT) at 0.04 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max: 1.42
Q3: 0.65
Median: 0.15
SMMT: 0.04
Q1: 0.02
Min: 0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max: 1.42
VTRS: 0.99
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
Current Ratio (MRQ)	5.99	1.55
Debt / Equity (MRQ)	0.04	0.99
Net Debt / EBITDA	--	2.64

Dividends

Dividend Yield (TTM)

Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS: 2.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Summit Therapeutics (SMMT) pays no dividend (payout 0.00%).

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS: 960.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
Dividend Yield (TTM)	0.00%	2.53%
Dividend Payout Ratio (TTM)	0.00%	960.00%

Valuation

P/E Ratio (TTM)

Neither Summit Therapeutics (SMMT) nor Viatris (VTRS) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
SMMT: --

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
VTRS: --

Summit Therapeutics (SMMT) vs. Viatris (VTRS): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Viatris (VTRS), whose P/S ratio of 1.55 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
SMMT: --

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
VTRS: 1.55
Min: 0.01

Summit Therapeutics (SMMT) vs. Viatris (VTRS): SMMT does not report P/S ratio, so it has no value marker; VTRS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile relative to book while Summit Therapeutics (SMMT) at 23.13 prices above its industry range — a wide valuation gap against assets.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT: 23.13
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
VTRS: 1.67
Min: -5.59

Summit Therapeutics (SMMT) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Summit Therapeutics (SMMT) and Viatris (VTRS)
Metric	SMMT	VTRS
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	--	1.55
P/B Ratio (MRQ)	23.13	1.67
Free Cash Flow Yield (TTM)	-1.64%	13.84%